Ethos Technologies Inc. (LIFE)
NASDAQ (CM) NASDAQ (CM) Primary 
XSTU Summary
Midnight Sun Mining to raise C$10M in 'bought deal' LIFE offering
Midnight Sun Mining Corp (TSX-V:MMA, OTCQB:MDNGF) announced that it has entered into an agreement with Haywood Securities, as lead underwriter and sole bookrunner, in which Midnight Sun will sell on a "bought deal" basis 7,408,000 company units, at a price of C$1.35 per unit, for total gross proceeds of C$10,000,800. The exploration company said net proceeds from the sale will be used by for advancing exploration across the company's Zambian exploration projects and for working capital and general corporate purposes.
Ethos Technologies Targets IPO Amid Positive Insurance Offerings
Ethos Technologies Inc. has filed for a $100 million IPO and provides a three-sided digital life insurance marketplace platform. LIFE is growing rapidly and profitably, with strong revenue, gross margin, and a recent swing to positive cash flow from operations. Risks include high revenue concentration among a few insurance carriers and agencies, and a dual-class share structure limiting public investor voting rights.
Gunnison Copper closes $8.66M LIFE private placement
Gunnison Copper Corp (TSX:GCU, OTCQB:GCUMF) told investors that it has closed its previously announced non-brokered private placement, raising gross proceeds of C$8.66 million through the sale of 28.87 million units priced at C$0.30 each. Each unit in the offering comprises one share and one common share purchase warrant, with each warrant exercisable at C$0.45 until July 18, 2028.
Ethos Technologies Inc. (LIFE) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Ethos Technologies Inc. ever had a stock split?
Ethos Technologies Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sanjay S. Shukla CEO | NASDAQ (CM) Exchange | 002120202 CUSIP |
| US Country | 56 Employees | - Last Dividend | 1 Jul 2019 Last Split | 7 May 2015 IPO Date |
Overview
aTyr Pharma, Inc. is a pioneering biotherapeutics company focused on the discovery and development of innovative medicines derived from novel immunological pathways. With a strong foundation in scientific research and a dedicated pursuit of groundbreaking treatments, aTyr Pharma is at the forefront of addressing unmet medical needs. Founded in 2005 and based in the heart of biotech innovation, San Diego, California, the company has positioned itself as a leader in harnessing immunological pathways to combat various diseases. Through its commitment to innovation and patient care, aTyr Pharma aims to unlock new possibilities in medicine and improve the lives of patients suffering from serious illnesses.
Products and Services
efzofitimod
As the leading therapeutic candidate of aTyr Pharma, efzofitimod is a forefront innovation in the treatment of pulmonary sarcoidosis and other interstitial lung diseases (ILDs). This selective modulator of NRP2 is currently under rigorous evaluation in a Phase III clinical trial specifically for pulmonary sarcoidosis, showcasing its potential as a pioneering treatment option. Furthermore, efzofitimod is exploring its versatility in a Phase 1b/2a clinical trial targeting a spectrum of ILDs, including chronic hypersensitivity pneumonitis and connective tissue disease-related ILD, underscoring aTyr Pharma’s dedication to expanding the therapeutic applications of its products.
ATYR0101
Emerging from aTyr Pharma’s innovative pipeline is ATYR0101, a fusion protein that originates from a domain of aspartyl-tRNA synthetase. This promising candidate is in the preclinical development stage for the treatment of fibrosis, demonstrating aTyr Pharma’s commitment to leveraging its unique understanding of immunological pathways to address this challenging medical condition.
ATYR0750
Another notable development from aTyr Pharma is ATYR0750, a protein derived from a domain of alanyl-tRNA synthetase aimed at treating liver disorders. This candidate is at the forefront of addressing liver conditions, further emphasizing the company’s broad expertise in targeting complex diseases through novel biological mechanisms.
In addition to its impressive portfolio of innovative therapeutics, aTyr Pharma has entered into a strategic collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. This partnership focuses on the development and commercialization of efzofitimod for ILDs in Japan, highlighting aTyr Pharma’s commitment to global healthcare solutions through synergistic collaborations.
Contact Information
